التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of fixed-dose ezetimibe+simvastatin in real-life hypercholesterolaemia treatment: a retrospective observational study in Taiwan. |
| المؤلفون: |
Shih, Yi-Chung, Lin, Huan-Sheng |
| المصدر: |
Clinical Lipidology; Dec2017, Vol. 12 Issue 1, p45-55, 11p |
| مصطلحات موضوعية: |
EZETIMIBE, SIMVASTATIN, HYPERCHOLESTEREMIA, LIPIDS, SERUM |
| مستخلص: |
Background:Combining statins with ezetimibe synergistically enhances lipid lowering, thereby reducing the need to prescribe maximal statin doses to achieve low-density lipoprotein cholesterol (LDL-C) goals. Real-world data on concurrent ezetimibe + statin therapy in Asians are sparse. Therefore, we evaluated the effectiveness of a single combined tablet of ezetimibe + simvastatin 10.0 + 20.0 mg (EZE + SIM) in Taiwanese patients with hypercholesterolaemia.Methods:We analysed retrospective data from patients who received EZE + SIM at a community hospital in New Taipei City, Taiwan, took EZE + SIM continuously for ≥24 weeks, and had before and after lipid data. Outcomes including lipid lowering, LDL-C goal attainment and safety (non-lipid serum biochemistry), were compared between diabetic versus non-diabetic patients and subgroups prescribed different EZE + SIM doses.Results:Among 157 EZE + SIM users, more than half had diabetes (64.3%) and/or hypertension (52%) and 24.1% had coronary artery disease. A mean EZE + SIM dose of 6.5 + 13.0 (median 5.0 + 10.0) mg/day for a mean of 51.6 weeks, significantly reduced total cholesterol (−30.4%), LDL-C (−36.2%) and triglycerides (−14.5%); consequently, attainment rates of LDL-C ≤ 100 mg/dl and ≤70 mg/dl goals were significantly higher after EZE + SIM treatment. There were no clinically significant changes in biomarkers of hepatic or renal function. Consistent with other reports, we observed indications of greater lipid-lowering efficacy and LDL-C goal attainment among patients with diabetes versus those without, at equivalent EZE + SIM doses.Conclusions:Our findings affirm the lipid-lowering efficacy of single-tablet fixed-dose EZE + SIM in real-world Taiwanese-Chinese patients with hypercholesterolaemia, especially at the recommended dose. Trends towards greater efficacy in diabetic than non-diabetic patients suggest that EZE + SIM may be a rational choice for treating patients with hypercholesterolaemia and diabetes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Lipidology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher 
Full Text Finder